How Ibrutinib-like Molecules Block Cancer-Causing Proteins

A chemical design for molecules that permanently latch onto and disable a specific protein called Btk, which is often responsible for the growth of certain blood cancers.

What it covers

This patent describes a class of chemical compounds designed to bind irreversibly to a protein known as Bruton's tyrosine kinase (Btk). By using a specific chemical component called a Michael acceptor, these molecules form a permanent covalent bond with the Btk protein, effectively shutting it down. This prevents the protein from signaling cancer cells to survive and multiply. For example, in patients with B-cell lymphomas, this mechanism stops the rogue cells from receiving the instructions they need to keep growing.

What it doesn't cover

• —Does not cover the Btk protein itself, but rather specific synthetic chemical structures that target it.
• —Does not cover reversible inhibitors that bind and release from the protein.
• —Does not cover non-Michael acceptor based inhibitors that lack the specific covalent binding mechanism described.
• —Does not cover general methods for treating cancer that do not utilize the specific chemical structures defined in the claims.

The clever bit

The innovation lies in the use of a Michael acceptor to create a permanent covalent bond with a specific cysteine residue on the Btk protein, ensuring the inhibitor stays attached and keeps the protein disabled indefinitely.

Why it matters

This patent is foundational to the development of targeted cancer therapies like Ibrutinib, which transformed the treatment of chronic lymphocytic leukemia. By creating a 'covalent' inhibitor, the inventors moved away from traditional chemotherapy, which kills all fast-growing cells, toward a precision medicine approach that targets a specific protein driver of disease. This shift has significantly improved survival rates and quality of life for patients with specific blood cancers.

Real-world examples

• 1.Ibrutinib (Imbruvica)
• 2.Targeted B-cell lymphoma therapies